1. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease;Hadinegoro;N Engl J Med,2015
2. Coudeville L, Baurin N, Vergu E. Fitting a transmission model to data from two large phase III vaccine efficacy studies. Vaccine, in press. http://dx.doi.org/10.1016/j.vaccine.2015.11.023.
3. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection;Guy;Nat Rev Microbiol,2016
4. Hadinegoro SR, Wartel Tram A, Frago C, Zambrano B, Langevin E, Gailhardou S, et al. Long-term safety of the CYD-TDV dengue vaccine in Asia-Pacific dengue endemic countries. In: 5th Pan American dengue research meeting; 2016. Abstract #R86.
5. Guy B, Moser J, Byers AM, Kachurin A, Pagnon A, de Montfort A, et al. Immunological investigations to understand the outcome of the phase III efficacy studies of the Sanofi Pasteur candidate dengue vaccine. In: ASTMH 64th annual meeting; 2015. Abstract #553.